• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women suffering from ADHD face a difficult decision on whether to keep or stop taking ADHD medication during pregnancy and breast-feeding. There aren't enough data regarding how to get adhd medication without diagnosis exposure over time may affect the pregnant fetus.

A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication during the uterus do not develop neurological developmental conditions like hearing or vision impairment seizures, febrile seizures, or IQ impairment. The authors acknowledge the need for higher-quality research.

Risk/Benefit Analysis

Pregnant women who use ADHD medications need to balance the benefits of taking them against the potential risks to the fetus. The doctors don't have the information to give clear advice however they can provide information about risks and benefits to aid pregnant women in making informed decisions.

A study published in Molecular Psychiatry concluded that women who took ADHD medication in early pregnancy were not at a higher risk of fetal malformations, or structural birth defects. Researchers used a vast population-based study of case-control to evaluate the incidence of major structural birth defects in infants born to mothers who had taken stimulants in early pregnancy, and those who can prescribe adhd medication did not. Clinical geneticists and pediatric cardiologists examined the cases to ensure an accurate case classification and to minimize the chance of bias.

However, the study had its limitations. The researchers were not able in the beginning to distinguish the effects triggered by the medication from the disorder. This makes it difficult for researchers to determine whether the few associations observed between the exposed groups were due to the use of medication or if they were affected by comorbidities. Additionally the study did not look at long-term offspring outcomes.

The study revealed that babies whose mothers took ADHD medication during pregnancy had a slightly greater risk of being admitted to the neonatal care unit (NICU), compared to those whose mothers did not use any medication during pregnancy, or had discontinued taking their medication prior to or during pregnancy. This was due to central nervous system-related disorders, and the increased risk for admission was not found to be affected by the type of stimulant medications were used during pregnancy.

Women who were taking stimulant ADHD medication during pregnancy were also at an elevated risk of having a caesarean birth or having a child with an low Apgar score (less than 7). These increases did appear to be independent of the type of medication used during pregnancy.

Researchers suggest that the minor risk of using mild adhd medication medication during pregnancies in the early stages could be offset by the more beneficial outcomes for both mother and baby from continuing treatment for the woman’s disorder. Physicians should discuss the issue with their patients and, when possible, help them develop strategies to improve coping skills which can reduce the impact of her disorder on her daily life and relationships.

Medication Interactions

Many doctors are confronted with the dilemma of whether to continue treatment or stop it during pregnancy as more women are diagnosed with ADHD. These decisions are frequently made without clear and reliable evidence. Instead, physicians must consider their own expertise and experience, as well as the experiences of other doctors and the research that has been conducted on the subject.

Particularly, the subject of potential risks for the baby can be tricky. The research on this issue is based on observations rather than controlled studies, and the results are in conflict. Additionally, the majority of studies limit their analysis to live births, which could underestimate the severity of teratogenic effects that could cause abortion or termination of the pregnancy. The study discussed in this journal club addresses these limitations by analyzing data on live and deceased births.

Conclusion Some studies have found an association between Adhd medication pregnancy medications and certain birth defects, other studies have not shown such a relationship. Most studies show that there is a neutral, or slightly negative, impact. As a result, a careful risk/benefit assessment is required in every situation.

It can be challenging, if not impossible for women with ADHD to stop taking their medication. In an article published in Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can increase depression, feelings of loneliness and family conflict for patients with ADHD. In addition, a decrease in medication may affect the ability to do work-related tasks and safely drive, which are important aspects of a normal life for many people suffering from ADHD.

She suggests that women who are unsure whether to continue taking medication or discontinue it due to pregnancy educate family members, coworkers, and friends about the condition, the effects on daily functioning, and the advantages of staying on the current treatment. It can also help a woman feel confident about her decision. Certain medications can be passed through the placenta. If the patient decides not to take her ADHD medication while pregnant and breastfeeding, it's important to be aware that the medication could be passed on to her baby.

Birth Defects Risk

As the use of ADHD drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD) grows as do concerns over the impact that these medications could have on fetuses. A study that was published in the journal Molecular Psychiatry adds to the body of information on this topic. Researchers utilized two massive datasets to analyze more than 4.3 million pregnancies and determine if the use of stimulant medications increased birth defects. While the overall risk remains low, the scientists discovered that the first-trimester exposure to ADHD medications was associated with an increased risk of certain heart defects, like ventriculo-septal defects (VSD).

The researchers behind the study found no association between early medication use and congenital abnormalities such as facial clefting or club foot. The results are consistent with previous studies that have shown an increase, but not significant, in the risk of developing cardiac malformations among women who began taking ADHD medications before pregnancy. This risk increased during the latter stages of pregnancy when many women began to stop taking their medication.

Women who took ADHD medication in the first trimester of their pregnancies were also more likely to undergo a caesarean section, a low Apgar score following delivery, and a baby who required help breathing at birth. The researchers of the study could not remove bias in selection since they limited the study to women who did not have any other medical conditions that might have contributed to the findings.

The researchers hope their research will serve to inform the clinical decisions of doctors who encounter pregnant women. They advise that while a discussion of the risks and benefits is crucial, the decision to stop or maintain medication should be based on each woman's requirements and the severity of her ADHD symptoms.

The authors also warn that, while stopping the medication is an alternative, it is not a recommended practice because of the high rate of depression and other mental health problems for women who are expecting or who are recently postpartum. Furthermore, research suggests that women who decide to stop taking their medication are more likely to have difficulties adapting to life without them after the baby's arrival.

Nursing

The responsibilities of being a new mother can be overwhelming. Women who suffer from ADHD who have to manage their symptoms while attending physician appointments and preparing for the arrival of their child and adjusting to new household routines can experience severe challenges. Many women choose to continue taking their ADHD medication during pregnancy.

The risk for nursing infant is low because the majority of stimulant medications passes through breast milk at a low level. However, the frequency of medication exposure to the newborn can vary depending on the dosage, frequency it is administered, and the time of the day the medication is administered. In addition, various drugs enter the infant's system via the gastrointestinal tract or breast milk. The impact of these medications on the health of a newborn isn't fully understood.

Due to the absence of evidence, some doctors might be tempted to stop taking stimulant medications during the course of pregnancy. This is a difficult decision for the patient, who must weigh the benefit of continuing her medication against the possible dangers to the foetus. As long as there is no more information, GPs should ask all pregnant patients about their experience with ADHD and if they plan or are taking to take medication during the perinatal period.

A growing number of studies have shown that most women can safely continue to take their ADHD medication while they are pregnant and nursing. This has led to an increasing number of patients are choosing to do so and after consulting with their doctor, they have found that the benefits of maintaining their current medication far outweigh any potential risks.

Women with ADHD who are planning to breastfeed should seek advice from a specialist psychiatrist prior to becoming pregnant. They should discuss their medication with their doctor and discuss the pros and cons for continuing treatment. This includes non-pharmacological strategies. Psychoeducation is also required to help pregnant people with ADHD recognize their symptoms and the root cause Learn about the available treatment options and reinforce existing strategies for coping. This should include a multidisciplinary approach, which includes the GP as well as obstetricians, psychiatry and obstetricians. The pregnancy counselling should consist of the discussion of a plan for management for both mother and child, monitoring for signs of deterioration, and, if necessary, adjustments to the medication regimen.